The HORIZON Recurrent Fracture Trial: Design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair

Current Medical Research and Opinion

Volumn 20, Issue 6, 2004, Pages 903-910

  Colón Emeric, Cathleen S ^a,b,d   Caminis, John ^c   Suh, Theodore T ^a,b,d   Pieper, Carl F ^a,b,d   Janning, Cheri ^d   Magaziner, Jay ^e   Adachi, Jonathan ^f   Rosario Jansen, Theresa ^c   Mesenbrink, Peter ^c   Horowitz, Zeb D ^g   Lyles, Kenneth W ^a,b,d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g Savient Pharmaceuticals Inc   (United States)

Author keywords

Aged; Clinical trials design; Diphosphonates; Hip fractures; Zoledronate

Indexed keywords

CALCITONIN; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TIBOLONE; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; HEALTH CARE UTILIZATION; HIP FRACTURE; HUMAN; OSTEOPOROSIS; OUTCOMES RESEARCH; PATIENT SELECTION; PLANNING; POSTOPERATIVE CARE; SECONDARY PREVENTION;

BONE DENSITY; CALCIUM; DEVELOPED COUNTRIES; DIPHOSPHONATES; FEMALE; HIP FRACTURES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; VITAMIN D;

EID: 3042642045     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125003683     Document Type: Article

References (31)

1. Jacobson S, Goldberg J, Miles TP, et al. Hip fracture incidence among the old and very old: a population based study of 745 435 cases. Am J Public Health 1990;80:871-3
2. Adachi JD, loannidis G, Berger C, et al. The influence of osteoporotic fractures on health related quality of life in community dwelling men and women across Canada. Osteoporos Int 2001;12:903-8
3. Hannan E, Magaziner J, Wang J, et al. Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes. J Am Med Assoc 2001;285:2736-42
4. Kane RL, Chen Q, Finch M, Blewett L, Burns R, Moskowitz M. Functional outcomes of posthospital care for stroke and hip fracture patients under medicare. J Am Geriatr Soc 1998;46:1525-33
5. Randell A, Nguyen T, Bhalerao N, et al. Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int 2000;11:460-6
6. Brainsky A, Glick H, Lydick E, et al. The economic cost of hip fractures in community dwelling older adults: a prospective study. J Am Geriatr Soc 1997;45:281-7
7. Zimmerman SI, Chandler J, Hawkes W, et al. Effect of fracture on the health care use of nursing home residents. Arch Int Med 2002;162:1502-8
8. Colon-Emeric C, Kuchibhatla M, Pieper C, et al. The contribution of hip fracture to subsequent fracture: data from two longitudinal studies. Osteoporos Int 2003;14(11):879-83
9. Fox KM, Magaziner J, Hawkes WG, et al. Loss of bone density and lean body mass after hip fracture. Osteoporos Int 2000;11:31-5
10. Dirschl D, Piedrahita L, Henderson R. Bone mineral density 6 years after a hip fracture: a prospective longitudinal study. Bone 2000;26:95-8
11. Karlsson M, Nilsson J, Sernbo I, Redlund-Johnell I, Johnell O, Obrant K. Changes of bone mineral mass and soft tissue composition after hip fracture. Bone 1996;18:19-22
12. Colon-Emeric C, Yballe L, Sloane R, et al. Expert physician recommendations and current practice patterns for evaluating and treating men with osteoporotic hip fracutre. J Am Geriatr Soc 2000;48:1261-3
13. Kamel H, Hussain M, Tariq S, et al. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med 2000;109:326-8
14. Torgerson D, Dolan P. Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis 1998;57:378-9
15. Harris S, Watts N, Geneant H, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. J Am Med Assoc 1999;282:1344-52
16. Black D, Cummings S, Karpf D, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41
17. Chestnut C, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000;109:267-76
18. Ettinger B, Black D, Mitlak B, et al. Reduction of vertebral fracture risk in postmenopausal women treated with raloxifene: results from a 3-year randomized clinical trial. J Am Med Assoc 1999;282:637-45
19. Neer R, Arnaud C, Zanchetta J, et al. Effect of parathyroid hormone on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 2001;344:1434-41
20. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. New Engl J Med 2000;343:604-10
21. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. New Engl J Med 2001;344(5):333-40
22. Levis S, Quandt SA, Thompson D et al. Alendronate reduces the risk of multiple symptomatic fractures: results for the Fracture Intervention Trial. J Am Geriatr Soc 2002;50(3):409-15
23. Reid I, Brown J, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New Engl J Med 2002;346:653-61
24. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Int Med 1990;113(12):941-8
25. NIH Consensus Statement: osteoporosis prevention, diagnosis and therapy, vol. 17. National Institutes of Health; 2000
26. Brown JP, Josse RG, et al. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002;167(Suppl 10):S1-34
27. Chapuy M, Arlot M, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New Engl J Med 1992;327:1637-42
28. Rosen C, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. New Engl J Med 2003;348:1503-4
29. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622-9
30. Genant H, Chun W, Van Kuijk C, Nevitt M. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-48
31. Szulc P, Munoz F, Marchand F, Delmas P. Semiquantitative evaluation of prevalent vertebral deformities in men and their relationship with osteoporosis: the MINOS study. Osteoporos Int 2001;12:302-10